507 related articles for article (PubMed ID: 25824054)
21. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.
Hawker K
Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD20 monoclonal antibodies in multiple sclerosis.
Moreno Torres I; García-Merino A
Expert Rev Neurother; 2017 Apr; 17(4):359-371. PubMed ID: 27718747
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
24. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
25. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C; Haggiag S; Ruggieri S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
[TBL] [Abstract][Full Text] [Related]
26. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects.
Weber MS; Menge T; Lehmann-Horn K; Kronsbein HC; Zettl U; Sellner J; Hemmer B; Stüve O
Curr Pharm Des; 2012; 18(2):209-19. PubMed ID: 22229582
[TBL] [Abstract][Full Text] [Related]
27. Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas.
Adem J; Eray M; Eeva J; Nuutinen U; Pelkonen J
Mol Immunol; 2017 Aug; 88():135-137. PubMed ID: 28644972
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Kasper LH; Shoemaker J
Neurology; 2010 Jan; 74 Suppl 1():S2-8. PubMed ID: 20038759
[TBL] [Abstract][Full Text] [Related]
29. Rituximab treatment for multiple sclerosis.
Ineichen BV; Moridi T; Granberg T; Piehl F
Mult Scler; 2020 Feb; 26(2):137-152. PubMed ID: 31237800
[TBL] [Abstract][Full Text] [Related]
30. [Targeting B cells in multiple sclerosis. Current concepts and strategies].
Menge T; Büdingen HC; Dalakas MC; Kieseier BC; Hartung HP
Nervenarzt; 2009 Feb; 80(2):190-8. PubMed ID: 19189075
[TBL] [Abstract][Full Text] [Related]
31. Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.
Lehmann-Horn K; Kinzel S; Weber MS
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946620
[TBL] [Abstract][Full Text] [Related]
32. B cells in multiple sclerosis.
Sospedra M
Curr Opin Neurol; 2018 Jun; 31(3):256-262. PubMed ID: 29629941
[TBL] [Abstract][Full Text] [Related]
33. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.
Memon AB; Javed A; Caon C; Srivastawa S; Bao F; Bernitsas E; Chorostecki J; Tselis A; Seraji-Bozorgzad N; Khan O
PLoS One; 2018; 13(1):e0190425. PubMed ID: 29309416
[TBL] [Abstract][Full Text] [Related]
35. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination.
Holley JE; Bremer E; Kendall AC; de Bruyn M; Helfrich W; Tarr JM; Newcombe J; Gutowski NJ; Eggleton P
Mult Scler Relat Disord; 2014 Sep; 3(5):650-8. PubMed ID: 26265276
[TBL] [Abstract][Full Text] [Related]
36. The BAFF / APRIL system as therapeutic target in multiple sclerosis.
Magliozzi R; Marastoni D; Calabrese M
Expert Opin Ther Targets; 2020 Nov; 24(11):1135-1145. PubMed ID: 32900236
[TBL] [Abstract][Full Text] [Related]
37. The potential role of B cell-targeted therapies in multiple sclerosis.
Boster A; Ankeny DP; Racke MK
Drugs; 2010 Dec; 70(18):2343-56. PubMed ID: 21142258
[TBL] [Abstract][Full Text] [Related]
38. B cells as therapeutic targets in autoimmune neurological disorders.
Dalakas MC
Nat Clin Pract Neurol; 2008 Oct; 4(10):557-67. PubMed ID: 18813230
[TBL] [Abstract][Full Text] [Related]
39. The role of B cells in multiple sclerosis: Current and future therapies.
Negron A; Robinson RR; Stüve O; Forsthuber TG
Cell Immunol; 2019 May; 339():10-23. PubMed ID: 31130183
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multiple sclerosis with anti-CD20 antibodies.
Barun B; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
